<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 30 Mar 2021 23:23:40 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>最新过评动态：30亿大品种迎齐鲁、倍特、海灵同日冲线！</title><link>https://mp.weixin.qq.com/s/3IuBBrKJ3wOxFqmMGQCkPA</link><description></description><content:encoded><![CDATA[最新过评动态：30亿大品种迎齐鲁、倍特、海灵同日冲线！]]></content:encoded><pubDate>Tue, 30 Mar 2021 21:35:59 +0800</pubDate></item><item><title>医保局点名 - 69个药被重点监控、关注</title><link>https://mp.weixin.qq.com/s/rIQGVMoIqeqptcsdJ20EGQ</link><description></description><content:encoded><![CDATA[医保局点名 - 69个药被重点监控、关注]]></content:encoded><pubDate>Tue, 30 Mar 2021 21:35:59 +0800</pubDate></item><item><title>这些国采非中选药，机会来了！</title><link>https://mp.weixin.qq.com/s/TNIfvSl45hAxmuEgyiPKiw</link><description></description><content:encoded><![CDATA[这些国采非中选药，机会来了！]]></content:encoded><pubDate>Tue, 30 Mar 2021 21:35:59 +0800</pubDate></item><item><title>16品种药价下调，最高降幅45.9%！</title><link>https://mp.weixin.qq.com/s/oZXhkl4rPjNKqMKTXD6NVw</link><description></description><content:encoded><![CDATA[16品种药价下调，最高降幅45.9%！]]></content:encoded><pubDate>Tue, 30 Mar 2021 21:35:59 +0800</pubDate></item><item><title>院内畅销药Top 20出炉，三大品种年销超20亿！</title><link>https://mp.weixin.qq.com/s/ZIu17ljxeLQR6Dd-62fSzA</link><description></description><content:encoded><![CDATA[院内畅销药Top 20出炉，三大品种年销超20亿！]]></content:encoded><pubDate>Mon, 29 Mar 2021 21:35:56 +0800</pubDate></item><item><title>三批国采最新进度一览，6品种完成度超1000%！</title><link>https://mp.weixin.qq.com/s/nvfHQ0HI-MYMYlRBkS_7Fw</link><description></description><content:encoded><![CDATA[三批国采最新进度一览，6品种完成度超1000%！]]></content:encoded><pubDate>Mon, 29 Mar 2021 21:35:56 +0800</pubDate></item><item><title>省际联盟集采试水，过评&amp;非过评药分A、B组入场竞赛...</title><link>https://mp.weixin.qq.com/s/sFWpfTYvGtYl1-4jm7zfsg</link><description></description><content:encoded><![CDATA[省际联盟集采试水，过评&非过评药分A、B组入场竞赛...]]></content:encoded><pubDate>Mon, 29 Mar 2021 21:35:56 +0800</pubDate></item><item><title>美国仿制药立项、调研及评估要点</title><link>https://mp.weixin.qq.com/s/XqRShKZ-uftLyDahWtNDiw</link><description></description><content:encoded><![CDATA[美国仿制药立项、调研及评估要点]]></content:encoded><pubDate>Mon, 29 Mar 2021 21:35:56 +0800</pubDate></item><item><title>（2021.3.26）一致性评价名单，8品种前三家过评！</title><link>https://mp.weixin.qq.com/s/jkjBKJ88hjJQEWq8EPMipw</link><description></description><content:encoded><![CDATA[（2021.3.26）一致性评价名单，8品种前三家过评！]]></content:encoded><pubDate>Fri, 26 Mar 2021 21:49:50 +0800</pubDate></item><item><title>阿立哌唑：躲不开集采？且慢，我有剂型优势！</title><link>https://mp.weixin.qq.com/s/TXrfKbUefJM4rfZpn0sfaQ</link><description></description><content:encoded><![CDATA[阿立哌唑：躲不开集采？且慢，我有剂型优势！]]></content:encoded><pubDate>Fri, 26 Mar 2021 21:49:50 +0800</pubDate></item><item><title>NMPA：2020年药品不良反应监测年度报告出炉</title><link>https://mp.weixin.qq.com/s/OQWcMsFwN4WINacBMCxKsg</link><description></description><content:encoded><![CDATA[NMPA：2020年药品不良反应监测年度报告出炉]]></content:encoded><pubDate>Fri, 26 Mar 2021 21:49:50 +0800</pubDate></item><item><title>推动未过评药集采，基药及医保品种优先入选...</title><link>https://mp.weixin.qq.com/s/XVlA9u9ngKy8f6ZS-GYxMw</link><description></description><content:encoded><![CDATA[推动未过评药集采，基药及医保品种优先入选...]]></content:encoded><pubDate>Fri, 26 Mar 2021 21:49:50 +0800</pubDate></item><item><title>一大批企业，掀起药品降价潮！</title><link>https://mp.weixin.qq.com/s/tJvUotcInO8jwR-EgH82ug</link><description></description><content:encoded><![CDATA[一大批企业，掀起药品降价潮！]]></content:encoded><pubDate>Thu, 25 Mar 2021 21:38:44 +0800</pubDate></item><item><title>新增60个过评药挂网</title><link>https://mp.weixin.qq.com/s/jhkQGFDzqcv4YfG4VJWM_g</link><description></description><content:encoded><![CDATA[新增60个过评药挂网]]></content:encoded><pubDate>Thu, 25 Mar 2021 21:38:44 +0800</pubDate></item><item><title>【ANDA】恒瑞-卡莫司汀在美获批上市</title><link>https://mp.weixin.qq.com/s/dMDVxgmumqg6O_OaTMdRQA</link><description></description><content:encoded><![CDATA[【ANDA】恒瑞-卡莫司汀在美获批上市]]></content:encoded><pubDate>Thu, 25 Mar 2021 21:38:44 +0800</pubDate></item><item><title>来康康！原料药企业转型新趋势</title><link>https://mp.weixin.qq.com/s/YsmPMOdA_IPc29L8aZjftQ</link><description></description><content:encoded><![CDATA[来康康！原料药企业转型新趋势]]></content:encoded><pubDate>Thu, 25 Mar 2021 21:38:44 +0800</pubDate></item><item><title>200亿神经系统药物市场，本土药企包揽销量Top 10品种！</title><link>https://mp.weixin.qq.com/s/3A1WsimVFxTp9X-emZNiSw</link><description></description><content:encoded><![CDATA[200亿神经系统药物市场，本土药企包揽销量Top 10品种！]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:39:12 +0800</pubDate></item><item><title>抗早产多肽-阿托西班，市场稳步增长，本土企业乘胜追击...</title><link>https://mp.weixin.qq.com/s/QgtzHGtsKSLOJWKnbW1DPg</link><description></description><content:encoded><![CDATA[抗早产多肽-阿托西班，市场稳步增长，本土企业乘胜追击...]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:39:12 +0800</pubDate></item><item><title>科伦：一抗癌热品获批，国内第3家过评！</title><link>https://mp.weixin.qq.com/s/Vgdk-yBJ8TPvmT-4I6bk7A</link><description></description><content:encoded><![CDATA[科伦：一抗癌热品获批，国内第3家过评！]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:39:12 +0800</pubDate></item><item><title>【一文回顾】化学药品注册分类</title><link>https://mp.weixin.qq.com/s/0U4qwkG-UV2Q3zEt3eOyZg</link><description></description><content:encoded><![CDATA[【一文回顾】化学药品注册分类]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:39:12 +0800</pubDate></item></channel></rss>